Brief: Salarius Pharmaceuticals Reports No Adverse Safety Signals From Two Good Laboratory Practice Toxicology Studies With Its Targeted Protein Degrader Sp-3164

Decoy Therapeutics

01/05/2023 13:40

May 1 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * SALARIUS PHARMACEUTICALS REPORTS NO ADVERSE SAFETY SIGNALS
FROM
TWO GOOD LABORATORY PRACTICE TOXICOLOGY STUDIES WITH ITS
TARGETED PROTEIN DEGRADER SP-3164
    * SALARIUS PHARMACEUTICALS INC - GLP TOXICOLOGY REPORTS WILL
BE
INCLUDED IN IND APPLICATION CO PLANS TO SUBMIT TO FDA IN Q2 OF
2023

Source text for Eikon:  ID:nGNX19r2L5 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))